Generation of precision preclinical cancer models using regulated in vivo base editing

Nat Biotechnol. 2024 Mar;42(3):437-447. doi: 10.1038/s41587-023-01900-x. Epub 2023 Aug 10.

Abstract

Although single-nucleotide variants (SNVs) make up the majority of cancer-associated genetic changes and have been comprehensively catalogued, little is known about their impact on tumor initiation and progression. To enable the functional interrogation of cancer-associated SNVs, we developed a mouse system for temporal and regulatable in vivo base editing. The inducible base editing (iBE) mouse carries a single expression-optimized cytosine base editor transgene under the control of a tetracycline response element and enables robust, doxycycline-dependent expression across a broad range of tissues in vivo. Combined with plasmid-based or synthetic guide RNAs, iBE drives efficient engineering of individual or multiple SNVs in intestinal, lung and pancreatic organoids. Temporal regulation of base editor activity allows controlled sequential genome editing ex vivo and in vivo, and delivery of sgRNAs directly to target tissues facilitates generation of in situ preclinical cancer models.

MeSH terms

  • Animals
  • CRISPR-Cas Systems / genetics
  • Gene Editing*
  • Lung
  • Mice
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • RNA, Guide, CRISPR-Cas Systems

Substances

  • RNA, Guide, CRISPR-Cas Systems